Navigation Links
Novavax to Join Russell 3000 Index
Date:6/26/2008

s various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional a
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
2. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
3. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
4. Novavax Reports First Quarter 2008 Financial Results
5. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
6. Novavax Opens Its First U.S. Vaccine Plant
7. Novavax CEO to Present at the World Vaccine Congress 2008
8. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
9. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
10. Novavax CEO to Present at BIO CEO & Investor Conference
11. Cardium Selected for Inclusion in Russell Microcap Index
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12Catilin Receives Renewable Energy Award for Pilot Plant 2
Breaking Biology News(10 mins):Vermicompost from pig manure grows healthy hibiscus 2Synthetic protein mimics structure, function of metalloprotein in nature 2Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 1Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 2Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 3What Makes a University Great 3F Americans Say Renowned Faculty Top Rank Research Center are Most Important According to New Survey from IP Advocate 13483 1What Makes a University Great 3F Americans Say Renowned Faculty Top Rank Research Center are Most Important According to New Survey from IP Advocate 13483 2What Makes a University Great 3F Americans Say Renowned Faculty Top Rank Research Center are Most Important According to New Survey from IP Advocate 13483 3What Makes a University Great 3F Americans Say Renowned Faculty Top Rank Research Center are Most Important According to New Survey from IP Advocate 13483 4What Makes a University Great 3F Americans Say Renowned Faculty Top Rank Research Center are Most Important According to New Survey from IP Advocate 13483 5William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 1William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 2William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 3William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 4